Botulinum toxin type a as a therapeutic agent against headache and related disorders

Toxins

Volumn 7, Issue 9, 2015, Pages 3818-3844

  Luvisetto, Siro ^a   Gazerani, Parisa ^b   Cianchetti, Carlo ^c   Pavone, Flaminia ^a  

^a CNR   (Italy)

^b AALBORG UNIVERSITY   (Denmark)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Animal pain model; Botulinum toxin; Cephalalgias; Clinical trials; Cluster headache; Headache; Human pain model; Migraine; Tension type headache

Indexed keywords

ACETYLCHOLINE; ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; SUBSTANCE P; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TRICYCLIC ANTIDEPRESSANT AGENT; VANILLOID RECEPTOR 1; MUSCLE RELAXANT AGENT;

ANXIETY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DEPRESSION; DISEASE CLASSIFICATION; DRUG INDUCED HEADACHE; DRUG RESPONSE; EPISODIC MIGRAINE; HEADACHE; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEURALGIA; NONHUMAN; OCCIPITAL SINUS; PAIN RECEPTOR; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDER; SPREADING CORTICAL DEPRESSION; SYSTEMATIC REVIEW (TOPIC); TENSION HEADACHE; TRANSFORMED MIGRAINE; TRIGEMINAL AUTONOMIC CEPHALALGIA; TRIGEMINAL NERVE; ANIMAL; CHEMISTRY; DISEASE MODEL; DYSTONIA; MIGRAINE DISORDERS; MUSCLE SPASTICITY;

ANIMALS; BOTULINUM TOXINS, TYPE A; DISEASE MODELS, ANIMAL; DYSTONIA; HEADACHE; HUMANS; MIGRAINE DISORDERS; MUSCLE SPASTICITY; NEURALGIA; NEUROMUSCULAR AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942415810     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins7093818     Document Type: Review

References (152)

1. Simpson, L.L. The life history of a botulinum toxin molecule. Toxicon 2013, 68, 40-59
2. Rossetto, O.; Pirazzini, M.; Montecucco, C. Botulinum neurotoxins: Genetic, structural and mechanistic insights. Nat. Rev. Microbiol. 2014, 12, 535-549
3. Cherington, M. Clinical spectrum of botulism. Muscle Nerve 1988, 21, 701-710
4. Dover, N.; Barash, J.R.; Hill, K.K.; Xie, G.; Arnon, S.S. Molecular characterization of a novel botulinum neurotoxin type H gene. J. Infect. Dis. 2014, 209, 192-202
5. Schiavo, G.; Matteoli, M.; Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80, 717-766
6. Johnson, E.A.; Montecucco, C. Chapter 11 botulism. Handb. Clin. Neurol. 2008, 91, 333-368
7. Kammerer, R.A.; Benoit, R.M. Botulinum neurotoxins: New questions arising from structural biology. Trends Biochem. Sci. 2014, 39, 517-526
8. Simpson, LL. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 167-93
9. Brunger, A.T. Structural insights into the molecular mechanism of Ca2+-dependent exocytosis. Curr. Opin. Neurobiol. 2000, 10, 293-302
10. Sudhof, T.C. The synaptic vesicle cycle. Annu. Rev. Neurosci. 2004, 27, 509-547
11. Pantano, S.; Montecucco, C. The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell. Mol. Life Sci. 2014, 71, 793-811
12. Lamanna, C.; McElroy, O.E.; Eklund, H.W. The purification and crystallization of Clostridium botulinum type A toxin. Science 1946, 103, 613-614
13. Buehler, H.J.; Schantz, E.J.; Lamanna, C. The elemental and amino acid composition of crystalline Clostridium botulinum type A toxin. J. Biol. Chem. 1947, 169, 295-302
14. Brooks, V.B. The action of botulinum toxin on motor-nerve filaments. J. Physiol. 1954, 123, 501-515
15. Scott, A.B. Botulinum toxin injection of eye muscles to correct strabismus. Trans. Am. Ophthalmol. Soc. 1981, 79, 734-770
16. Jankovic, J.; Brin, M.F. Botulinum Toxin: Historical Perspective and Potential New Indications. Muscle Nerve 1997, 20 (Suppl. 6), S129-S145
17. Erbguth, F.J. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov. Disord. 2004, 19 (Suppl. 8), S2-S6
18. Humeau, Y; Doussau, F; Grant, N.J.; Poulain, B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000, 82, 427-446
19. Popoff, M.R.; Poulain, B. Bacterial toxins and the nervous system: Neurotoxins and multipotential toxins interacting with neuronal cells. Toxins 2010, 2, 683-737
20. Montecucco, C.; Molgò, J. Botulinal neurotoxins: Revival of an old killer. Curr. Opin. Pharmacol. 2005, 5, 274-279
21. Truong, D.D.; Jost, W.H. Botulinum toxin: Clinical use. Parkinsonism Relat. Disord. 2006, 12, 331-355
22. Jabbari, B. Botulinum neurotoxins in the treatment of refractory pain. Nat. Clin. Pract. Neurol. 2008, 4, 676-685
23. Blitzer, A.; Brin, M.F.; Keen, M.S.; Aviv, J.E. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch. Otolaryngol. Head Neck Surg. 1993, 119, 1018-1022
24. Binder, W.J.; Brin, M.F.; Blitzer, A.; Schenrock, L.; Diamond, B. Botulinum toxin type A (BTX-A) for migraine: An open label assessment. Mov. Disord. 1998, 13, 241
25. Binder, W.J.; Brin, M.F.; Blitzer, A.; Schoenrock, L.D.; Pogoda, J.M. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study. Otolaryngol. Head Neck Surg. 2000, 123, 669-676
26. International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013, 33, 629-808
27. Pietrobon, D.; Moskowitz, M.A. Pathophysiology of migraine. Annu. Rev. Physiol. 2013, 75, 365-391
28. Olesen, J; Burstein, R; Ashina, M; Tfelt-Hansen, P. Origin of pain in migraine: Evidence for peripheral sensitization. Lancet Neurol. 2009, 8, 679-690
29. Cianchetti, C. The role of the neurovascular scalp structures in migraine. Cephalalgia 2012, 32, 778-784
30. Shevel, E. The extracranial vascular theory of migraine-A great story confirmed by the facts. Headache 2011, 51, 409-417
31. Loder, E.; Rizzoli, P. Tension-type headache. Br. Med. J. 2008, 336, 88-92
32. Leroux, E; Ducros, A. Cluster headache. Orphanet J. Rare Dis. 2008, 3, 20
33. Brin, M.F.; Fahn, S.; Moskowitz, C.; Friedman, A.; Shale, H.M.; Greene, P.E.; Blitzer, A.; List, T.; Lange, D.; Lovelace, R.E. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv. Neurol. 1988, 50, 599-608
34. Tarsy, D.; First, E.R. Painful cervical dystonia: Clinical features and response to treatment with botulinum toxin. Mov. Disord. 1999, 14, 1043-1045
35. Freund, B.; Schwartz, M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J. Pain 2003, 4, 159-165
36. Edvison, L.; Ekman, R; Goadsby, P.J. Measurement of vasoactive neuropeptides in biological materials: Problems and pitfalls from 30 years of experience and novel future approaches. Chephalalgia 2010, 30, 761-766
37. Ho, T.W.; Edvinsson, L.; Goadsby, P.J. CGRP and its receptors provide new insights into migraine pathophysiology. Nat. Rev. Neurol. 2010, 6, 573-582
38. Wang, M. Cortical spreading depression and calcitonin gene-related peptide: A brief review of current progress. Neuropeptides 2013, 47, 463-466
39. Bigal, M.E.; Walter, S.; Rapoport, A.M. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache 2013, 53, 1230-1244
40. Jones, E.A.; Shyti, R.; van Zeijl, R.J.; van Heiningen, S.H.; Ferrari, M.D.; Deelder, A.M.; Tolner, E.A.; van den Maagdenberg, A.M.; McDonnell, L.A. Imaging mass spectrometry to visualize biomolecule distributions in mouse brain tissue following hemispheric cortical spreading depression. J. Proteom. 2012, 75, 5027-5035
41. Shatillo, A.; Koroleva, K; Giniatullina, R.; Naumenko, N.; Slastnikova, A.A.; Aliev, R.R.; Bart, G.; Atalay, M.; Gu, C.; Khazipov, R.; et al. Cortical spreading depression induces oxidative stress in the trigeminal nociceptive system. Neuroscience 2013, 253, 341-349
42. Welch, M.J.; Purkiss, J.R.; Foster, K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000, 38, 245-258
43. Purkiss, J.; Welch, M.; Doward, S.; Foster, K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: Involvement of two distinct mechanisms. Biochem. Pharmacol. 2000, 59, 1403-1406
44. Durham, P.L.; Cady, R.; Cady, R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache 2004, 44, 35-43
45. Meng, J.; Wang, J.; Lawrence, G.; Dolly, J.O. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J. Cell Sci. 2007, 120, 2864-2874
46. Meng, J.; Ovsepian, S.V.; Wang, J.; Pickering, M.; Sasse, A.; Aoki, K.R.; Lawrence, G.W.; Dolly, J.O. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J. Neurosci. 2009, 29, 4981-4992
47. Meng, J.; Dolly, J.O.; Wang, J. Selective cleavage of SNAREs in sensory neurons unveils protein complexes mediating peptide exocytosis triggered by different stimuli. Mol. Neurobiol. 2014, 50, 574-588
48. Shao, Y.F.; Zhang, Y.; Zhao, P.; Yan, W.J.; Kong, X.P.; Fan, L.L.; Hou, Y.P. Botulinum toxin type A therapy in migraine: Preclinical and clinical trials. Iran. Red Crescent Med. J. 2013, 15, e7704
49. Gazerani, P.; Au, S.; Dong, X.; Kumar, U.; Arendt-Nielsen, L.; Cairns, B.E. Botulinum neurotoxin type A (BoNT/A) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis. Pain 2010, 151, 606-616
50. Morenilla-Palao, C.; Planells-Cases, R.; Garcia-Sanz, N.; Ferrer-Montiel, A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J. Biol. Chem. 2004, 279, 25665-25672
51. Caterina, M.J.; Schumacher, M.A.; Tominaga, M.; Rosen, T.A.; Levine, J.D.; Julius, D. The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature 1997, 389, 816-824
52. Camprubí-Robles, M.; Planells-Cases, R.; Ferrer-Montiel, A. Differential contribution of SNARE-dependent exocytosis to inflammatory potentiation of TRPV1 in nociceptors. FASEB J. 2009, 23, 3722-3733
53. Shimizu, T.; Shibata, M.; Toriumi, H.; Iwashita, T.; Funakubo, M.; Sato, H.; Kuroi, T.; Ebine, T.; Koizumi, K.; Suzuki, N. Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol. Dis. 2012, 48, 367-378
54. Zhang, D.X.; Gutterman, D.D. Transient receptor potential channel activation and endothelium-dependent dilation in the systemic circulation. J. Cardiovasc. Pharmacol. 2011, 57, 133-139
55. Geppetti, P.; Rossi, E.; Chiarugi, A.; Benemei, S. Antidromic vasodilatation and the migraine mechanism. J. Headache Pain 2012, 13, 103-111
56. Tóth, A.; Czikora, A.; Pásztor, E.T.; Dienes, B.; Bai, P.; Csernoch, L.; Rutkai, I.; Csató, V.; Mányiné, I.S.; Pórszász, R.; et al. Vanilloid receptor-1 (TRPV1) expression and function in the vasculature of the rat. J. Histochem. Cytochem. 2014, 62, 129-144
57. Pozsgai, G.; Bodkin, J.V.; Graepel, R.; Bevan, S.; Andersson, D.A.; Brain, S.D. Evidence for the pathophysiological relevance of TRPA1 receptors in the cardiovascular system in vivo. Cardiovasc. Res. 2010, 7, 760-768
58. Baraldi, P.G.; Preti, D.; Materazzi, S.; Geppetti, P. Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J. Med. Chem. 2010, 53, 5085-5107
59. Luvisetto, S.; Vacca, V.; Cianchetti, C. Analgesic effects of botulinum neurotoxin type A in a model of allyl isothiocyanate- and capsaicin-induced pain in mice. Toxicon 2015, 94, 23-28
60. Goadsby, P.J. Emerging therapies for migraine. Nat. Clin. Pract. Neurol. 2007, 3, 610-619
61. Meents, J.E.; Neeb, L.; Reuter, U. TRPV1 in migraine pathophysiology. Trends Mol. Med. 2010, 16, 153-159
62. Del Fiacco, M.; Quartu, M.; Boi, M.; Serra, M.P.; Melis, T.; Boccaletti, R.; Shevel, E.; Cianchetti, C. TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. J. Neurol. Neurosurg. Psychiatr. 2015, 86, 393-397
63. Dux, M.; Sántha, P.; Jancsó, G. The role of chemosensitive afferent nerves and TRP ion channels in the pathomechanism of headaches. Pflugers. Arch. 2012, 464, 239-248
64. Benemei, S.; De Cesaris, F.; Fusi, C.; Rossi, E.; Lupi, C.; Geppetti, P. TRPA1 and other TRP channels in migraine. J. Headache Pain 2013, 14, 71-79
65. Benemei, S.; Fusi, C.; Trevisan, G.; Geppetti, P. The TRPA1 channel in migraine mechanism and treatment. Br. J. Pharmacol. 2014, 171, 2552-2567
66. Burstein, R.; Zhang, X.; Levy, D.; Aoki, K.R.; Brin, M.F. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains. Cephalalgia. 2014, 34, 853-869
67. Matak, I.; Bach-Rojecky, L.; Filipovic, B.; Lackovic, Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin a. Neuroscience 2011, 186, 201-207
68. Matak, I.; Lackovic, Z. Botulinum toxin a, brain and pain. Prog. Neurobiol. 2014, 119-120, 39-59
69. Drinovac, V.; Bach-Rojecky, L.; Matak, I.; Lackovic, Z. Involvement of mu-opioid receptors in antinociceptive action of botulinum toxin type A. Neuropharmacology 2013, 70, 331-337
70. Ji, R.R.; Berta, T.; Nedergaard, M. Glia and pain: Is chronic pain a gliopathy? Pain 2013, 154 (Suppl. 1), S10-S28
71. Silva, L.B.; Poulsen, J.N.; Arendt-Nielsen, L.; Gazerani, P. Botulinum neurotoxin type a modulates vesicular release of glutamate from satellite glial cells. J. Cell Mol. Med. 2015, doi:10.1111/jcmm.12562
72. Marinelli, S.; Vacca, V.; Ricordy, R.; Uggenti, C.; Tata, A.M.; Luvisetto, S.; Pavone, F. The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS ONE 2012, 7, e47977
73. Negus, S.S.; Vanderah, T.W.; Brandt, M.R.; Bilsky, E.J.; Becerra, L.; Borsook, D. Preclinical assessment of candidate analgesic drugs: Recent advances and future challenges. J. Pharmacol. Exp. Ther. 2006, 319, 507-514
74. Mogil, J.S.; Davis, K.D.; Derbyshire, S.W. The necessity of animal models in pain research. Pain 2010, 151, 12-17
75. Blackburn-Munro, G. Pain-like behaviours in animals - how human are they? Trends Pharmacol. Sci. 2004, 25, 299-305
76. Mogil, J.S.; Crager, S.E. What should we be measuring in behavioral studies of chronic pain in animals? Pain 2004, 112, 12-15
77. Staahl, C.; Drewes, A.M. Experimental human pain models: A review of standardised methods for preclinical testing of analgesics. Basic Clin. Pharmacol. Toxicol. 2004, 95, 97-111
78. Arendt-Nielsen, L.; Curatolo, M.; Drewes, A. Human experimental pain models in drug development: Translational pain research. Curr. Opin. Investig. Drugs 2007, 8, 41-53
79. Staahl, C.; Reddy, H.; Andersen, S.D.; Arendt-Nielsen, L.; Drewes, A.M. Multi-modal and tissue-differentiated experimental pain assessment: Reproducibility of a new concept for assessment of analgesics. Basic Clin. Pharmacol. Toxicol. 2006, 98, 201-211
80. Arendt-Nielsen, L.; Yarnitsky, D. Experimental and clinical applications of quantitative sensory testing applied to skin, muscles and viscera. J. Pain 2009, 10, 556-572
81. Arendt-Nielsen, L.; Hoeck, H.C. Optimizing the early phase development of new analgesics by human pain biomarkers. Expert Rev. Neurother. 2011, 11, 1631-1651
82. Bittencourt da Silva, L.; Karshenas, A.; Bach, F.W.; Rasmussen, S.; Arendt-Nielsen, L.; Gazerani, P. Blockade of glutamate release by botulinum neurotoxin type A in humans: A dermal microdialysis study. Pain Res. Manag. 2014, 19, 126-132
83. Blersch, W.; Schulte-Mattler, W.J.; Przywara, S.; May, A.; Bigalke, H.; Wohlfarth, K. Botulinum toxin a and the cutaneous nociception in humans: A prospective, double-blind, placebo-controlled, randomized study. J. Neurol. Sci. 2002, 205, 59-63
84. Da Silva, L.B.; Kulas, D.; Karshenas, A.; Cairns, B.E.; Bach, F.W.; Arendt-Nielsen, L.; Gazerani, P. Time course analysis of the effects of botulinum neurotoxin type A on pain and vasomotor responses evoked by glutamate injection into human temporalis muscles. Toxins 2014, 6, 592-607
85. Gazerani, P.; Pedersen, N.S.; Staahl, C.; Drewes, A.M.; Arendt-Nielsen, L. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009, 141, 60-69
86. Gazerani, P.; Staahl, C.; Drewes, A.M.; Arendt-Nielsen, L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006, 122, 315-325
87. Kramer, H.H.; Angerer, C.; Erbguth, F.; Schmelz, M.; Birklein, F. Botulinum toxin a reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J. Neurol. 2003, 250, 188-193
88. Schulte-Mattler, W.J.; Opatz, O.; Blersch, W.; May, A.; Bigalke, H.; Wohlfahrt, K. Botulinum toxin a does not alter capsaicin-induced pain perception in human skin. J. Neurol. Sci. 2007, 260, 38-42
89. Sycha, T.; Samal, D.; Chizh, B.; Lehr, S.; Gustorff, B.; Schnider, P.; Auff, E. A lack of antinociceptive or antiinflammatory effect of botulinum toxin a in an inflammatory human pain model. Anesth. Analg. 2006, 102, 509-516
90. Voller, B.; Sycha, T.; Gustorff, B.; Schmetterer, L.; Lehr, S.; Eichler, H.G.; Auff, E.; Schnider, P. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin a. Neurology 2003, 61, 940-944
91. Aoki, K.R.; Francis, J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat. Disord. 2011, 17 (Suppl. 1), S28-S33
92. Ambache, N. A further survey of the action of clostridium botulinum toxin upon different types of autonomic nerve fibre. J. Physiol. 1951, 113, 1-17
93. Pavone, F.; Luvisetto, S. Botulinum neurotoxin for pain management: Insights from animal models. Toxins 2010, 2, 2890-2913
94. Paterson, K.; Lolignier, S.; Wood, J.N.; McMahon, S.B.; Bennett, D.L. Botulinum toxin-a treatment reduces human mechanical pain sensitivity and mechanotransduction. Ann. Neurol. 2014, 75, 591-596
95. O’Neill, J.; Brock, C.; Olesen, A.E.; Andresen, T.; Nilsson, M.; Dickenson, A.H. Unravelling the mystery of capsaicin: A tool to understand and treat pain. Pharmacol. Rev. 2012, 64, 939-971
96. Bach-Rojecky, L.; Lackovic, Z. Antinociceptive effect of botulinum toxin type A in rat model of carrageenan and capsaicin induced pain. Croat. Med. J. 2005, 46, 201-208
97. Tugnoli, V.; Capone, J.G.; Eleopra, R.; Quatrale, R.; Sensi, M.; Gastaldo, E.; Tola, M.R.; Geppetti, P. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain 2007, 130, 76-83
98. Matak, I.; Rossetto, O.; Lackovic, Z. Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons. Pain 2014, 155, 1516-1526
99. Mørch, C.D.; Gazerani, P.; Nielsen, T.A.; Arendt-Nielsen, L. The UVB cutaneous inflammatory pain model: A reproducibility study in healthy volunteers. Int. J. Physiol. Pathophysiol. Pharmacol. 2013, 5, 203-215
100. Castrillon, E.E.; Cairns, B.E.; Wang, K.; Arendt-Nielsen, L.; Svensson, P. Comparison of glutamate-evoked pain between the temporalis and masseter muscles in men and women. Pain 2012, 153, 823-829
101. Frampton, J.E. Onabotulinumtoxina (botox®): A review of its use in the prophylaxis of headaches in adults with chronic migraine. Drugs 2012, 72, 825-845
102. Cui, M.; Khanijou, S.; Rubino, J.; Aoki, K.R. Subcutaneous administration of botulinum toxin a reduces formalin-induced pain. Pain 2004, 107, 125-133
103. Yiangou, Y.; Anand, U.; Otto, W.R.; Sinisi, M.; Fox, M.; Birch, R.; Foster, K.A.; Mukerji, G.; Akbar, A.; Agarwal, S.K.; et al. Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons. J. Pain Res. 2011, 4, 347-55
104. Cernuda-Morollón, E.; Ramón, C.; Martínez-Camblor, P.; Serrano-Pertierra, E.; Larrosa, D.; Pascual, J. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 2015, 156, 820-824
105. Aoki, K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005, 26, 785-793
106. Cairns, B.E.; Gazerani, P. Botulinum neurotoxin A for chronic migraine headaches: Does it work and how? Pain Manag. 2014, 4, 377-380
107. Walsh, S. FDA Approves Botox to Treat Chronic Migraine; U.S. Food and Drug Administration: Silver Spring, MD, USA, 2010
108. Jensen, R.; Olesen, J. Tension-type headache: An update on mechanisms and treatment. Curr. Opin. Neurol. 2000, 13, 285-289
109. Relja, M. Treatment of tension type headache by local injection of botulinum toxin. Eur. J. Neurol. 1997, 4 (Suppl. 2), S71-S77
110. Relja, M.; Telarović, S. Botulinum toxin in tension-type headache. J. Neurol. 2004, 251 (Suppl. 1), I12-I14
111. Freund, B.J.; Schwartz, M. Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A. Headache 2002, 42, 1033-1037
112. Smuts, J.; Baker, M.; Smuts, H.; Stassen, J.; Rossouw, E.; Barnard, P. Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur. J. Neurol. 1999, 6 (Suppl. 4), S99-S102
113. Schmitt, W.J.; Slowey, E.; Fravi, N.; Weber, S.; Burgunder, J.M. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: A double-blind, placebo controlled trial. Headache 2001, 41, 658-664
114. Rollnik, J.D.; Tanneberger, O.; Schubert, M.; Schneider, U.; Dengler, R. Treatment of tension-type headache with botulinum toxin type A: A double-blind, placebo-controlled study. Headache 2000, 40, 300-305
115. Gobel, H.; Lindner, V.; Krack, P; Heinze, A.; Gaartz, N.; Deuschl, G. Treatment of chronic tension-type headache with botulinum toxin. Cephalalgia 1999, 19, 455
116. Padberg, M.; de Bruijn, S.F.T.M.; de Haan, R.J.; Tavy, D.L.J. Treatment of chronic tension-type headache with botulinum toxin: A double-blind, placebo-controlled clinical trial. Cephalalgia 2004, 24, 675-680
117. Schulte-Mattler, W.J.; Krack, P.; BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin A: A randomized, double-blind, placebo-controlled multicenter study. Pain 2004, 109, 110-114
118. Silberstein, S.D.; Göbel, H.; Jensen, R.; Elkind, A.H.; DeGryse, R.; Walcott, J.M.C.M.; Turkel, C. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: A multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006, 26, 790-800
119. Jackson, J.L.; Kuriyama, A.; Hayashino, Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: A meta-analysis. JAMA 2012, 307, 1736-1745
120. Sostak, P.; Krause, P.; Förderreuther, S.; Reinisch, V.; Straube, A. Botulinum toxin type-A therapy in cluster headache: An open study. J. Headache Pain 2007, 8, 236-241
121. Gadient, P.M.; Smith, J.H. The neuralgias: Diagnosis and management. Curr. Neurol. Neurosci. Rep. 2014, 14, 459-467
122. Cheshire, W.P. Trigeminal neuralgia: For one nerve a multitude of treatments. Expert Rev. Neurother. 2007, 7, 1565-1579
123. Borodic, G.E.; Acquadro, M.A. The use of botulinum toxin for the treatment of chronic facial pain. J. Pain 2002, 3, 21-27
124. Piovesan, E.J.; Teive, H.G.; Kowacs, P.A.; Della Coletta, M.V.; Werneck, L.C.; Silberstein, S.D. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 2005, 65, 1306-1308
125. Türk, U.; Ilhan, S.; Alp, R.; Sur, H. Botulinum toxin and intractable trigeminal neuralgia. Clin. Neuropharmacol. 2005, 28, 161-162
126. Zuniga, C.; Diaz, S.; Piedimonte, F.; Micheli, F. Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq. NeuroPsiquiatr. 2008, 66, 500-503
127. Bohluli, B.; Motamedi, M.H.; Bagheri, S.C.; Bayat, M.; Lassemi, E.; Navi, F.; Moharamnejad, N. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: Preliminary report. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2011, 111, 47-50
128. N Allam, N.; Brasil-Neto, J.P.; Brown, G.; Tomaz, C. Injections of botulinum toxin type A produce pain alleviation in intractable trigeminal neuralgia. Clin. J. Pain 2005, 21, 182-184
129. Ngeow, W.C.; Nair, R. Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg., Oral Med., Oral Pathol., Oral Radiol., Endod. 2010, 109, e47-e50
130. Wu, C.J.; Lian, Y.J.; Zheng, Y.K.; Zhang, H.F.; Chen, Y.; Xie, N.C.; Wang, L.J. Botulinum toxin type A for the treatment of trigeminal neuralgias: Results from a randomized, double-blind, placebo-controlled trial. Cephalgia 2012, 32, 443-450
131. Zhang, H.; Lian, Y.; Ma, Y.; Chen, Y.; He, C.; Xie, N.; Wu, C. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: Observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J. Headache Pain. 2014, 15, 65-71
132. Shehata, H.S.; El-Tamawy, M.S.; Shalaby, N.M.; Ramzy, G. Botulinum toxin-type A: Could it be an effective treatment option in intractable trigeminal neuralgia? J. Headache Pain 2013, 14, 92-98
133. Xia, J.H.; He, C.H.; Zhang, H.F.; Lian, Y.J.; Chen, Y.; Wu, C.J.; Ma, Y.Q. Botulinum Toxin A in the Treatment of Trigeminal Neuralgia. Int. J. Neurosci. 2015, 19, 1-6
134. Volcy, M.; Tepper, S.J.; Rapoport, A.M.; Sheftell, F.D.; Bigal, M.E. Botulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia: A case report with pathophysiological considerations. Cephalalgia. 2006, 26, 336-340
135. Kapural, L.; Stillman, M.; Kapural, M.; McIntyre, P.; Guirgius, M.; Mekhail, N. Botulinum toxin occipital nerve block for the treatment of severe occipital neuralgia: A case series. Pain Pract. 2007, 7, 337-340
136. Taylor, M.; Silva, S.; Cottrell, C. Botulinum toxin type-a (botox) in the treatment of occipital neuralgia: A pilot study. Headache 2008, 48, 1476-1481
137. Ramachandran, R; Yaksh, T.L. Therapeutic use of botulinum toxin in migraine: Mechanism of action. Br. J. Pharmacol. 2014, 171, 4177-4192
138. Naumann, M.; So, Y.; Argoff, C.E.; Childers, M.K.; Dykstra, D.D.; Gronseth, G.S.; Jabbari, B.; Kaufmann, H.C.; Schurch, B.; Silberstein, S.D.; et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology 2008, 70, 1707-1714
139. Aurora, S.K.; Dodick, D.W.; Turkel, C.C.; DeGryse, R.E.; Silberstein, S.D.; Lipton, R.B.; Diener, H.C.; Brin, M.F. PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the doubleblind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010, 30, 793-803
140. Diener, H.C.; Dodick, D.W.; Aurora, S.K.; Turkel, C.C.; DeGryse, R.E.; Lipton, R.B.; Silberstein, S.D.; Brin, M.F. PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the doubleblind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010, 30, 804-814
141. Dodick, D.W.; Turkel, C.C.; DeGryse, R.E.; Aurora, S.K.; Silberstein, S.D.; Lipton, R.B.; Diener, H.C.; Brin, M.F.; Group, P.C.M.S. Onabotulinumtoxina for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the preempt clinical program. Headache 2010, 50, 921-936
142. Silberstein, S.D.; Blumenfeld, A.M.; Cady, R.K.; Turner, I.M.; Lipton, R.B.; Diener, H.C.; Aurora, S.K.; Sirimanne, M.; DeGryse, R.E.; Turkel, C.C.; et al. Onabotulinumtoxina for treatment of chronic migraine: Preempt 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J. Neurol. Sci. 2013, 331, 48-56
143. Aurora, S.K.; Dodick, D.W.; Diener, H.C.; DeGryse, R.E.; Turkel, C.C.; Lipton, R.B.; Silberstein, S.D. OnabotulinumtoxinA for chronic migraine: Efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta. Neurol. Scand. 2014, 129, 61-70
144. Blumenfeld, A.; Inocelda, A.; Cunanan, C.; Purdy, C.; Dalfonso, L.; Magar, R. The Durability of OnabotulinumtoxinA for the Treatment of Chronic Migraine: CLARITY Pilot Study (P7.186). Neurology 2014, 82 (Suppl. 10), 7
145. Blumenfeld, A.; Aurora, S.K.; Laranjo, K.; Papapetropoulos, S. Rationale for study and design of COMPEL: An open-Label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. F1000Posters 2012, 3, 654
146. Blumenfeld, A.; Stark, R.; Reppine, A.; Halstead, M; Holdbrook, F.; Aurora, S.K. Efficacy and Safety of OnabotulinumtoxinA in a Long-Term, Open-Label Study for the Prophylaxis of Headaches in Adult Chronic Migraine Patients: An Interim Analysis of the COMPEL Study (P1.306). Neurology 2015, 84 (Suppl. 14), 1-306
147. Cernuda-Morollón, E.; Ramón, C.; Larrosa, D.; Alvarez, R.; Riesco, N.; Pascual, J. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year? Cephalalgia 2015, 35, 864-868
148. Blumenfeld, A.M.; Binder, W.; Silberstein, S.D.; Blitzer, A. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 2003, 43, 884-891
149. Silberstein, S.D. Botulinum toxin in headache management. In Botulinum. Toxin: Therapeutic Clinical Practice and Science; Saunders: Philadelphia, PA, USA, 2009; p 218
150. Blumenfeld, A.; Silberstein, S.; Dodick, D.; Aurora, S.; Turkel, C.C.; Binder, W.J. Method of injection of onabotulinumtoxina for chronic migraine: A safe, well-tolerated, and effective treatment paradigm on the preempt clinical program. Headache 2010, 50, 1406-1418
151. Jabbari, B. Migraine and other primary headaches. In Botulinum. Toxin Treatment of Pain Disorders; Springer Publisher: Berlin, Germany, 2015; pp. 49-67
152. Silberstein, S.D. TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. Some like it hot! Chronic migraine increases TRPV1 receptors in the scalp. J. Neurol. Neurosurg. Psychiatr. 2015, 86, 361